ZA962141B - Treatment and prevention of prostatic cancer. - Google Patents
Treatment and prevention of prostatic cancer.Info
- Publication number
- ZA962141B ZA962141B ZA9602141A ZA962141A ZA962141B ZA 962141 B ZA962141 B ZA 962141B ZA 9602141 A ZA9602141 A ZA 9602141A ZA 962141 A ZA962141 A ZA 962141A ZA 962141 B ZA962141 B ZA 962141B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- treatment
- prostatic cancer
- prostatic
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/408,745 US5629007A (en) | 1995-03-21 | 1995-03-21 | Method of preventing prostatic cancer development |
| US08/407,822 US5635197A (en) | 1995-03-21 | 1995-03-21 | Treatment and prevention of prostatic cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA962141B true ZA962141B (en) | 1997-09-15 |
Family
ID=27020024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9602141A ZA962141B (en) | 1995-03-21 | 1996-03-15 | Treatment and prevention of prostatic cancer. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0733365A3 (de) |
| JP (1) | JPH08277220A (de) |
| KR (1) | KR960034202A (de) |
| AU (1) | AU695860B2 (de) |
| CA (1) | CA2172211A1 (de) |
| CZ (1) | CZ287977B6 (de) |
| HU (1) | HUP9600702A3 (de) |
| IL (1) | IL117537A (de) |
| MX (1) | MX9601031A (de) |
| NO (1) | NO961113L (de) |
| SG (1) | SG47093A1 (de) |
| TW (1) | TW450809B (de) |
| YU (1) | YU16196A (de) |
| ZA (1) | ZA962141B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
| PE13899A1 (es) * | 1996-10-30 | 1999-02-25 | Lilly Co Eli | Sintesis de benzo [f] quinolinonas |
| WO2000006167A1 (en) * | 1998-07-29 | 2000-02-10 | Merk & Co., Inc. | Tricyclic compounds |
| US6436489B1 (en) | 1999-03-24 | 2002-08-20 | Clariant International Ltd. | Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0591583B1 (de) * | 1991-08-21 | 2001-12-19 | Eli Lilly And Company | Benzo(f)quinolinone als 5-Alpha-reduktase Inhibitoren |
| US5239075A (en) * | 1991-08-21 | 1993-08-24 | Eli Lilly And Company | Process for the preparation of benzo (f) quinolinones |
-
1996
- 1996-03-15 TW TW085103095A patent/TW450809B/zh active
- 1996-03-15 SG SG1996006549A patent/SG47093A1/en unknown
- 1996-03-15 ZA ZA9602141A patent/ZA962141B/xx unknown
- 1996-03-18 IL IL11753796A patent/IL117537A/xx not_active IP Right Cessation
- 1996-03-19 KR KR1019960007405A patent/KR960034202A/ko not_active Application Discontinuation
- 1996-03-19 CZ CZ1996825A patent/CZ287977B6/cs unknown
- 1996-03-19 AU AU48168/96A patent/AU695860B2/en not_active Ceased
- 1996-03-19 MX MX9601031A patent/MX9601031A/es not_active IP Right Cessation
- 1996-03-19 YU YU16196A patent/YU16196A/sh unknown
- 1996-03-19 NO NO961113A patent/NO961113L/no not_active Application Discontinuation
- 1996-03-19 EP EP96301846A patent/EP0733365A3/de not_active Withdrawn
- 1996-03-20 CA CA002172211A patent/CA2172211A1/en not_active Abandoned
- 1996-03-20 HU HU9600702A patent/HUP9600702A3/hu unknown
- 1996-03-21 JP JP8064428A patent/JPH08277220A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0733365A2 (de) | 1996-09-25 |
| AU695860B2 (en) | 1998-08-27 |
| KR960034202A (ko) | 1996-10-22 |
| HU9600702D0 (en) | 1996-05-28 |
| SG47093A1 (en) | 1998-03-20 |
| CZ287977B6 (cs) | 2001-03-14 |
| IL117537A0 (en) | 1996-07-23 |
| YU16196A (sh) | 1998-11-05 |
| IL117537A (en) | 2001-01-11 |
| TW450809B (en) | 2001-08-21 |
| CZ82596A3 (en) | 1996-10-16 |
| MX9601031A (es) | 1997-02-28 |
| JPH08277220A (ja) | 1996-10-22 |
| HUP9600702A2 (en) | 1996-12-30 |
| CA2172211A1 (en) | 1996-09-22 |
| HUP9600702A3 (en) | 1997-04-28 |
| AU4816896A (en) | 1996-10-03 |
| NO961113L (no) | 1996-09-23 |
| NO961113D0 (no) | 1996-03-19 |
| EP0733365A3 (de) | 1997-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0831904A4 (de) | Behandlung und diagnose von prostatakrebs | |
| ZA965088B (en) | Methods of preventing or treating allergles | |
| ZA9610249B (en) | Treatment of vegetables. | |
| HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
| AU2402395A (en) | Cancer treatment and metastasis prevention | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| IL129351A0 (en) | Hiv and cancer treatment | |
| AU6435398A (en) | Prevention and treatment of hepatocellular cancer | |
| EP0855910A4 (de) | Verwendbare konjugate zur behandlung der gutartigen prostatehyperplasie | |
| AU7166896A (en) | Cancer treatment | |
| ZA962141B (en) | Treatment and prevention of prostatic cancer. | |
| EP0804546A4 (de) | Menschliche, prostata-spezifische reduktase | |
| EP0800396A4 (de) | Behandlung hyperandrogener zustände | |
| EP0833641A4 (de) | Behandlung und vorbeugung von erkrankungen der prostata | |
| EP0679083A4 (de) | Prävention und behandlung von sepsis. | |
| AU4417996A (en) | Treatment of prostate cancer | |
| GB9516572D0 (en) | Prevention and/or treatment of disease | |
| ZA964382B (en) | Lymphotoxin and thrombopoietin for use in the treatment of cancer. | |
| GB9510961D0 (en) | Hemorrhoid treatment and prevention | |
| AU2003204325A1 (en) | Detection and treatment of cancer | |
| AUPO851597A0 (en) | Treatment of prostate cancer | |
| ZA937015B (en) | Treatment and diagnosis of cancer | |
| ZA972152B (en) | Treatment and prophylaxis of pancreatitis. | |
| ZA988293B (en) | Compositions and methods for the treatment of tumor. | |
| GB9503201D0 (en) | Anti-smoking treatment,therapy and illness prevention |